In the Appendix 4E and Annual Report some wording (page 14) seemed to allude to part of the revenue attributable to sales in Australia. "OncoSil had a cash balance of $12.2 million as at 30 June 2021. During the year, OncoSil made modest inaugural revenue from the sale of the OncoSil™ device of $213k in Australia and New Zealand".
OSL Price at posting:
5.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)